Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cogentus Pharmaceuticals has initiated dosing in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168, a once-daily capsule that combines clopidogrel to improve the gastrointestinal safety of antiplatelet therapy.
Subscribe to our email newsletter
The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. Separately, Cogentus has begun Cogent-1, a global Phase III trial that will evaluate the clinical benefits of CGT-2168 with aspirin compared to Plavix with aspirin.
Mark Goldsmith, chairman and CEO of Cogentus, said: “We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today.”